Stock Performance and Market Context
On the trading day, Vivimed Labs Ltd (Stock ID: 612893) recorded a price increase of ₹0.28, translating to a 3.94% rise, reaching the upper price band of ₹7.45. This gain outpaced the Pharmaceuticals & Drugs sector, which saw a modest 0.36% increase, and contrasted sharply with the Sensex’s decline of 0.70%. The stock’s one-day return stood at 4.23%, underscoring its outperformance relative to key benchmarks.
Notably, Vivimed Labs has been on a positive trajectory for two consecutive days, accumulating a 6.35% return over this period. However, the stock remains trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating that despite the recent gains, it is yet to break through longer-term resistance levels.
Trading Volumes and Liquidity Insights
The total traded volume for the day was approximately 0.96215 lakh shares, with a turnover of ₹0.0697 crore. While this volume reflects active participation, delivery volumes have notably declined. On 5 March 2026, delivery volume was 45,710 shares, down by 71% compared to the five-day average, signalling a drop in investor commitment to holding the stock long-term. Despite this, the stock’s liquidity remains adequate for trading sizes up to ₹0 crore, based on 2% of the five-day average traded value.
Upper Circuit Trigger and Regulatory Freeze
Vivimed Labs Ltd’s price hitting the upper circuit limit triggered an automatic regulatory freeze on further buying for the remainder of the trading session. This mechanism is designed to curb excessive volatility and protect investors from speculative spikes. The freeze indicates that demand exceeded supply significantly, with buy orders remaining unfilled at the upper price band, reflecting strong investor enthusiasm.
The upper circuit limit for the stock is set at 5% of the previous closing price, and the stock’s 3.94% gain on the day was close to this threshold, with the price band allowing a maximum movement of ₹0.38 from the previous close. The closing price of ₹7.38 was just shy of the high price of ₹7.45, underscoring the intensity of buying pressure that pushed the stock to its regulatory limit.
Rising fast and still accelerating! This Small Cap from FMCG sector is riding pure momentum right now. Jump in before the rally reaches its peak!
- - Accelerating price action
- - Pure momentum play
- - Pre-peak entry opportunity
Fundamental and Market Capitalisation Overview
Vivimed Labs Ltd operates within the Pharmaceuticals & Drugs industry and is classified as a micro-cap company with a market capitalisation of approximately ₹61 crore. Despite the recent price surge, the company’s Mojo Score remains low at 14.0, with a Mojo Grade of Strong Sell as of 5 February 2026, downgraded from Sell. This rating reflects underlying concerns about the company’s fundamentals and market positioning.
The Market Cap Grade is 4, indicating limited scale and liquidity compared to larger peers. Investors should weigh the recent price momentum against these fundamental metrics before making investment decisions.
Technical Indicators and Investor Sentiment
While the stock’s recent gains demonstrate strong short-term buying interest, technical indicators suggest caution. The stock is trading below all major moving averages, which often act as resistance levels. Additionally, the sharp decline in delivery volumes points to a reduction in long-term investor participation, possibly indicating that the rally is driven more by speculative trading than sustained confidence.
Nevertheless, the upper circuit hit and unfilled demand highlight a surge in market interest, which could attract momentum traders and short-term investors looking to capitalise on volatility.
Holding Vivimed Labs Ltd from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Investor Takeaways and Outlook
Vivimed Labs Ltd’s upper circuit hit on 6 March 2026 is a clear signal of strong buying interest and short-term bullish sentiment. However, investors should approach with caution given the company’s micro-cap status, weak Mojo Grade, and declining delivery volumes. The stock’s inability to break above key moving averages suggests that the rally may face resistance ahead.
For investors considering entry, it is crucial to monitor whether the stock can sustain momentum beyond the upper circuit event and translate speculative interest into fundamental strength. Additionally, the regulatory freeze following the upper circuit hit limits immediate buying, which may temper volatility in the short term.
Overall, while the price action is encouraging for momentum traders, a comprehensive analysis of fundamentals and peer comparisons is advisable before committing capital.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
